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Abstract
Background: The BRCA2 and MRE11 proteins participate in the repair of double-strand DNA
breaks by homologous recombination. Germline BRCA2 mutations predispose to ovarian, breast
and pancreatic cancer, while a germline MRE11 mutation is associated with an ataxia telangiectasia-
like disorder. Somatic mutations of BRCA2 are rare in typical sporadic cancers. In tumors having
microsatellite instability (MSI), somatic truncating mutations in a poly [A] tract of BRCA2 are
reported on occasion.
Results: We analyzed gastrointestinal MSI cancers by whole gene BRCA2 sequencing, finding
heterozygous truncating mutations in seven (47%) of 15 patients. There was no cellular functional
defect in RAD51 focus-formation in three heterozygously mutated lines studied, although other
potential functions of the BRCA2 protein could still be affected. A prior report of mutations in
primary MSI tumors affecting the IVS5-(5–15) poly [T] tract of the MRE11 gene was confirmed and
extended by analysis of the genomic sequence and protein expression in MSI cancer cell lines.
Statistical analysis of the published MRE11 mutation rate in MSI tumors did not provide evidence
for a selective pressure favoring biallelic mutations at this repeat.
Conclusion:  Perhaps conflicting with common suspicions, the data are not compatible with
selective pressures during tumorigenesis promoting the functional loss of BRCA2 and MRE11 in MSI
tumors. Instead, these data fit closely with an absence of selective pressures acting on BRCA2 and
MRE11 gene status during tumorigenesis.
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Background
The mismatch repair genes are genomic caretakers that
function most visibly in the repair of simple nucleotide
repeats. Neoplastic cells with defects in this pathway have
a particular type of genetic instability resulting in elevated
rates of sequence mutations and very high rates of muta-
tions in microsatellites (simple repetitive sequences);
hence the term microsatellite instability (MSI). Cancers
displaying MSI usually harbor mutations in at least some
of the specific genes that contain microsatellites in their
coding sequence, such as TGFBR2, BAX, ACVR2, IGF2R,
MSH3 and MSH6 [1,2]. Because the MSI phenotype is
fully adequate to explain the accumulation of new muta-
tions in these genes, the mere presence of the mutations
does not imply that the genes have any special role in
tumorigenesis. High mutation rates of a repetitive
sequence in a particular gene could be caused by the
length of the repeat as well as the adjacent sequence
(which may allow slippage during DNA replication) and
are not necessarily the result of selective pressure acting on
these genes during tumorigenesis [3,4]. An exception
exists for a few genes, in particular the TGFBR2, ACVR2,
and BAX genes, where the prevalence rate (as contrasted
with the mere presence) of homozygous mutations and
biallelic compound mutations has been statistically dem-
onstrated to exceed the rate expected by the chance acqui-
sition of the two individual mutant alleles [5]. For these
latter genes, one can infer that during tumorigenesis,
selective pressures favored the emergence of subclones
having gained a biallelic mutation. Specifically, we can
justifiably refer to TGFBR2, ACVR2, and BAX as tumor-
suppressor genes. In the cases of TGFBR2 and ACVR2,
instances of somatic homozygous mutation affecting
non-repetitive coding sequences are reported also in non-
MSI tumors, those exhibiting chromosomal instability
(CIN), strengthening the argument for a tumor-suppres-
sive role for these genes [5].
The roles of the BRCA2 and MRE11 (MRE11A) genes in
tumorigenesis are not so clear-cut. Many persons with a
germline inactivating mutation of BRCA2 do not get can-
cer. There is little evidence that BRCA2 plays a gatekeeper
role for neoplasia. We know, for instance, that unlike with
germline mutations of the gatekeeper genes APC, MEN1
and RB1, the germline BRCA2 mutations do not give rise
to a recognizable syndrome of multiple incipient neo-
plasms in any particular organ. Instead, it is possible that
BRCA2  plays a tumorigenic role primarily late in the
development of a neoplasm. In the case of one patient
that had a germline BRCA2 mutation and a pancreatic
cancer, the loss of the wildtype allele was observed only in
the cancer and in the most histologically advanced of a
number of neoplastic lesions studied; the histologically
earlier stages of neoplasia still retained the wild-type allele
[6]. This case, along with the finding of the wild-type
allele among early pancreatic neoplasia in other patients
having a germline BRCA2 mutation, supported a "late"
role for BRCA2 mutation in tumorigenesis.
This "late" role is rationalized by the known impairment
of the pace of the cell division cycle when the BRCA2 gene
is knocked out genetically in nonneoplastic cells [7]. As
one mechanistic explanation for this empirical observa-
tion, the successful transit from S phase to M phase
requires the repair of a number of double-strand DNA
breaks that arise normally in each cell cycle. The homolo-
gous recombination DNA repair system, which utilizes
the endonuclease MRE11 and the RAD51-assembly tem-
plate BRCA2, is an important means to repair such breaks
after DNA replication [8,9]. In the absence of this system,
normal cellular checkpoints may restrict the progress of
the cell cycle. Thus the role of BRCA2  defects during
breast, pancreatic, and ovarian tumorigenesis may be pri-
marily to increase the genetic instability, but to do so only
once the neoplastic clone has accumulated a number of
defects in checkpoint functions, a situation that would
exist in late, rather than early, stages of tumorigenesis.
Although mutations in BRCA2 do not provide a growth
advantage in nonneoplastic cells, the BRCA2 gene is often
discussed as a "tumor-suppressor" gene. If it were so, in
MSI tumors one would expect to find biallelic mutations
at a rate higher than expected from the individual rates of
mutant alleles [5,10]. Alternatively, if BRCA2 were prima-
rily serving a role in genome maintenance (rather than in
growth regulation or some other proper and expected
"tumor-suppressor" function), its functional loss might
often be selected against. In this latter scenario, the preva-
lence of biallelic mutations would be found to be unex-
pectedly low even in the face of a high prevalence of
mutant single alleles.
It would thus be especially instructive to interrogate the
numerical data available from the MSI tumors; these
human tumors are a form of natural long-term experi-
ment. A heterozygous somatic mutation in an [A]8 tract at
codon 602–605 of the BRCA2 gene was discovered in an
ovarian MSI tumor by Takahashi et al [11]. This short
repeat was subsequently examined by several groups: a
somatic mutation prevalence rate of 0–5% in MSI cases
was reported [12-15]. In a study of 12 MSI endometrial
tumors by Koul et al, six somatic BRCA2-mutations were
found in five tumors [16]; one intronic mutation identi-
fied four times, however, was later criticized as being unre-
lated to gene function [17]. Owing to the incomplete
examination of the large BRCA2  gene sequence in the
prior studies, the findings were inadequate to infer any
tendencies towards or against the functional inactivation
of BRCA2 that might act during tumorigenesis. Here, we
study BRCA2 frameshift mutations in cell lines of gas-BMC Genetics 2006, 7:3 http://www.biomedcentral.com/1471-2156/7/3
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trointestinal MSI tumors and provide functional testing of
BRCA2-related cellular responses.
Briefly, we also revisited the recently reported genetic
alterations affecting a mononucleotide repeat tract of the
MRE11  gene. These mutations, like the heterozygous
mutations of BRCA2 in MSI tumors, raise somewhat sim-
ilar questions regarding the role of a mutated gene in tum-
origenesis. The MRE11 gene encodes a protein involved in
the repair of double-stranded breaks and has an intronic
[T]11 tract four basepairs from the 5' end of exon 5, harbor-
ing nucleotide deletions in colorectal MSI cases [18].
These observed deletions were associated with expression
of an altered transcript of the MRE11 gene, splicing out
exon 5 and leading to decreased or absent MRE11 protein
expression [18].
Results and discussion
Heterozygous BRCA2 mutations in gastrointestinal MSI 
cancer cells
MSI tumors have a dramatically increased rate of muta-
tions, especially in genes containing microsatellites.
Inconveniently for researchers, mutations in such tracts
do not necessarily imply a causal role for the affected
genes, as noted in the first study describing such altera-
tions in human tumors [19]. Yet, if mutations in a given
gene prove beneficial to the developing neoplasm, newly
mutated subclones of cancer cells having acquired this
mutation can outcompete other clones that do not pos-
sess the mutation. This selective pressure can be mathe-
matically proven from the mutational prevalence rates
found in human tumors, as has been done for the TGF-
βRII and ACVRII genes [5]. If mutations in BRCA2 would
be positively selected (i.e., selected for) in MSI tumors,
one would expect biallelic mutations in BRCA2 to fre-
quently be found. Alternatively, heterozygous mutations
could have a dominant-negative effect or could lead to
haplo-insufficiency with some loss of function, while per-
haps still providing a growth advantage to the developing
cancer cell.
Upon whole gene sequencing of BRCA2 in 14 gastrointes-
tinal MSI cancer cell lines and one pancreatic adenocarci-
noma xenograft, a single heterozygous frameshift
mutation was found in the xenograft and in each of five
cell lines. Two heterozygous mutations were encountered
in one additional cell line (Table 1). Four of these muta-
tions occurred in nucleotide repeats different from those
previously reported; mutations at nucleotides 1807–1813
(codons 602–605) [11] and 5355–5361 (codons1785–
1787) [16] had been reported previously [9-14]. The
novel MSI mutations included deletions within an [A]7
tract at nucleotides 5067–5073 (codons 1689–1691), an
[A]7 tract at nucleotides 9103–9110 (codons 3035–3037),
and a non-repetitive site at nucleotides 3599–3600
(codon 1200). All of these frameshift mutations are
expected to result in truncation of the BRCA2 protein and
abrogation of its function. The mRNA expression of four
different BRCA2-mutations was assayed by reverse tran-
scriptase-PCR in four cell lines: LS174T (9110delA), RKO
(5361delA), MIP101 (5361delA, 3599delGT) and PL3
(5073delA); all mutant alleles were found to be expressed.
In addition to the deleterious frameshift mutations, sev-
eral missense variants were found (Table 1). Most of these
sequence changes are known variants of the BRCA2 gene
that do not segregate with cancer in affected families and
were judged as unlikely to have an effect on BRCA2 pro-
tein function.
Retention of BRCA2 function as assayed by RAD51 focus 
formation
RAD51 is a protein involved in homologous recombina-
tion that forms nuclear foci in response to DNA damage;
BRCA2 function is needed for the formation of these foci
[20]. To evaluate the possibility of a loss of BRCA2-gene
function, we determined RAD51 focus-formation in
response to treatment with mitomycin C and ionizing
radiation in three mutated MSI cancer cell lines (PL3,
MIP101 and RKO), in one MSI cancer cell line without
BRCA2 mutations (PL5) and in two nonneoplastic BRCA2
wildtype cells (FN1 and VH10). None of these cell lines
Table 1: BRCA2 and MRE11 mutations in MIN cell lines
Tumor Cell Line/Xenograft* Truncating BRCA2 Mutations Other BRCA2 Variants MRE11A Mutations**
MIP101 (colorectal) 5355delA, 3599delGT R2784G T9/T10/T11
LS174T (colorectal) 9110delA T9/T10
RKO (colorectal) 5355delA T8/T9/T10
HCT116 (colorectal) 9110delA T9/T10
KM12 (colorectal) 5355delA K1565N
PL3 (pancreatic) 5073delA T9/T10
PL5 (pancreatic) None detected T9/T10
PX196 (pancreatic) 1813delA S326R
Vaco481 (colorectal) None detected I2944F, K1777del3
*Six additional MSI cell lines had no truncating mutation or other variant of the BRCA2 sequence.
**Nucleotide deletions of the [T]11 tract. The mutations in LS174T, MIP101, and HCT116 were reported previously [18, 22, 23]BMC Genetics 2006, 7:3 http://www.biomedcentral.com/1471-2156/7/3
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had a defect in RAD51 focus formation (Figure 1 and data
not shown), evidence of intact BRCA2 function in all of
these cell lines. The BRCA2-deficient cell lines CAPAN1
[21] and FA-D1 (derived from a Fanconi anemia patient
with BRCA2 mutations) lacked RAD51 focus-formation
and served as positive controls having functional pathway
abnormalities [20]. Additionally, we determined the sen-
sitivity of PL3, PL5, MIP101 and RKO to mitomycin C and
irradiation; heterozygous mutations in the BRCA2 gene
did not result in an increase in sensitivity to these genoto-
xic agents (data not shown).
MRE11 intronic nucleotide deletions and expression in 
MSI cancer cells
Another DNA repair gene, MRE11, contains an intronic
poly [T]-tract near the 5' boundary of exon 5; shortening
of this repeat occurs frequently in MSI tumors. To confirm
the alterations of this repeat, we sequenced the IVS5-(5–
15) poly [T] tract (normally a T11) of the MRE11 gene in
six MSI cell lines. We confirmed the reported nucleotide
deletions in LS174T (T9/T10), MIP101 (T9/T10/T11), and
HCT116 (T9/T10) [18,22], and uncovered additional
biallelic variants in RKO (T8/T9/T10), PL3 (T9/T10), and
PL5 (T9/T10) cell lines (Table 1). The finding of more
than two alleles in both MIP101 and RKO could be due
either to trisomy or heterogeneous cell populations. The
presence of three alleles in MIP101 is a confirmation of
the study by Giannini et al. [18] and is therefore likely to
be caused by trisomy rather than the presence of different
cell populations. By MRE11 immunoblot, we confirmed
full-size MRE11 protein as being expressed in all cell lines
(data not shown). MIP101 had heterozygous mutations
Rad51 focus formation in BRCA2-mutated cell lines Figure 1
Rad51 focus formation in BRCA2-mutated cell lines. a. Cells were treated for 8 hours with MMC (2.4 µg/mL) and 
immunolabeled for RAD51 (green) and DAPI (blue). MIP101 and RKO are colorectal MSI cancer cells harboring BRCA2 
frameshift mutations (see text). BRCA2-/- cells (EUFA423/FA-D1) are derived from a Fanconi anemia patient with complementa-
tion group D1/BRCA2 b. Cells were treated with MMC (2.4 µg/mL) or ionizing radiation (12 Gy); after recovery for 8 or 24 
hours, cells were stained for RAD51. RAD51 foci were counted and the percentage of cells with > 5 foci was determined. FN1 
and VH10 are nonneoplastic BRCA2-wildtype cells.BMC Genetics 2006, 7:3 http://www.biomedcentral.com/1471-2156/7/3
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affecting two of the three alleles and thus retained a
wildtype allele of the MRE11 gene; MRE11 protein was
expressed at a higher level in MIP101 than in cell lines
having all alleles mutated (data not shown). The MRE11
protein is still expressed in these cell lines, however, and
although possible disturbances in the MRE11/NBS1/
RAD50 complex have been shown by Giannini et al. [23],
an unequivocal defect in MRE11 function has not yet
been shown. An indirect argument in favor of some
retained function was provided by a demonstration that
MRE11 was essential for maintenance of chromosomal
DNA in vertebrate cells [9]. There is also a report of
MRE11 binding to the MLH1 protein (a member of the
mismatch repair system), which if significant might com-
plicate the MRE11 functional testing in some MSI tumors
[24]. Additional functional assessment of the MRE11 pro-
tein in MSI tumors was beyond the scope of this study.
Statistical analysis of mutational prevalence rates
We observed the following prevalence rates of BRCA2
sequences: biallelic wildtype, 53.3%; heterozygous,
46.7%; biallelic mutant, 0%. Given the assumptions
under the theory of quantitative selection constants
(QSC) [5,10] and deriving the expectations solely from
this rate of biallelic wildtype sequences, the expected het-
erozygous mutation prevalence would be 39.4% and the
biallelic mutant prevalence due to a chance distribution of
mutations among the two alleles (i.e., under the null
hypothesis) would be 7.3%. According to the binomial
test for QSC data and N = 15 cases, the likelihood (bino-
mial sum) for the absence of biallelic mutations in this
panel was 0.331. An examination of the statistical power,
given a 53.3% prevalence of homozygous wildtype alleles
and an observed 0% rate of homozygous mutant tumors,
showed that 40 MSI tumors would be the minimal
number required to produce a binomial sum of less than
0.05. Thus, the number of cases needed to evaluate the
BRCA2-related selective pressures (one would be advised
to use a multiple of the minimal necessary number) vastly
exceeded the number of MSI cell lines available (15 MSI
cell lines were available). Numerical arguments such as
those considered here would benefit from higher num-
bers of analyzed tumors. Attaining such numbers in an
independent larger tumor panel would be difficult: to be
able to functionally test tumors with BRCA2 mutations,
cell lines would be needed. However, the number of
known MSI cancer cell lines is currently limited.
Another argument for gastrointestinal selection against
deficiency of the BRCA2 gene comes from a recent report
by Hay et al., studying mice in which BRCA2 was bialleli-
cally mutated in the small intestine [25]. A p53-depend-
ent increase in apoptosis was noted, ultimately resulting
in the removal of BRCA2-deficient cells, perhaps protect-
ing against tumorigenesis. Although this study was not
done in the setting of an MSI background, it does support
the hypothesis that the loss of BRCA2 function is often
selected against.
A prior report provided the prevalence rates of MRE11
mutations in colorectal cancer: biallelic wildtype, 16.3%;
heterozygous mutant, 44.9%; biallelic mutant, 38.8%
[23]. Given this rate of biallelic wildtype sequences, the
expected heterozygous mutation prevalence would be
48.1% and the expected biallelic mutant rate due to a
chance distribution of mutations among the two alleles
would be 35.6%. The observed and expected rates are
highly concordant. The null hypothesis, that selection
pressures during tumorigenesis had not acted to influence
the ratio between heterozygous (i.e., non-inactivating)
and homozygous (inactivating) mutations, was not
rejected and indeed appeared to explain the observed data
rather well. Prior studies of human MSI cancer cell lines
demonstrated that the prevalence rate of mutations was
positively correlated with the length of the repeat [26].
The most complete of these studies did not examine
repeats longer than an eight mono-nucleotide run, but it
could reasonably be extrapolated that an 11-mononucle-
otide run, such as that present in the MRE11 gene, would
have a mutational prevalence rate much higher than 50%
of MSI tumors even in the absence of selective pressures
favoring mutations of a given gene. These prior authors
noted, however, that there was a strong and unexplained
contextual variation in mutational prevalence rates, and
thus the mere prevalence rate of the mutations cannot
directly offer evidence for or against selective pressures
having acted during tumorigenesis upon the functional
status of a given gene.
In 2001, Fukuda et al. discovered three missense muta-
tions in the MRE11 gene in two breast carcinomas and
one lymphoma [27]. At least one of these three mutations
was somatic; it is unclear whether these mutations
occurred in MSI defective tumors. Wang et al. recently dis-
covered eight somatic mutations in the MRE11 gene to be
present in seven colorectal CIN cancers (168 tumors were
studied), a rate not easily explained by chance alone, as
random somatic mutations in non-MSI cancers are very
rare [28]. Further studies are warranted to investigate the
role of functional MRE11 defects in the development of
CIN and MSI tumors, but the mutational data do not yet
support a role in MSI cancer cells.
Conclusion
We found heterozygous frameshift mutations in the
BRCA2 gene to be present in 47% of gastrointestinal MSI
cancer cell lines, a much higher percentage than previ-
ously reported. During tumorigenesis, mismatch repair
deficient cancer cells evidently experiment extensively
with BRCA2 mutations, perhaps as a consequence of theBMC Genetics 2006, 7:3 http://www.biomedcentral.com/1471-2156/7/3
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high number of repetitive sequences in the BRCA2 gene in
combination with locus susceptibility to mutation. No
impairment in BRCA2 function as assayed by RAD51
focus formation was detected, however. One cell line,
MIP101, had two mutations in the BRCA2 gene, but no
defect in RAD51 focus formation. We thus surmise that
these two mutations exist in cis on one allele, with the
cells retaining the other BRCA2 allele in wildtype form.
Although the trend is not yet statistically significant, our
data raise the possibility that retention of BRCA2 function
is selected for, and that biallelic BRCA2  mutation is
selected against, during tumorigenesis of MSI tumors.
Mutations of MRE11 are probably selection-neutral, and
thus may not be functionally important in tumorigenesis.
Our findings are not compatible with a strong selective
pressure favoring abrogation of BRCA2 function in MSI
tumors. Loss of BRCA2 function in addition to a defect in
mismatch repair is perhaps detrimental to cell mainte-
nance: a limited level of genetic instability could be bene-
ficial to tumorigenesis, but excessive DNA repair defects
would not. While the functional inactivation of the
BRCA2 gene inhibited the growth of normal cells [7], it
might accelerate the rate of genetic changes in developing
CIN tumors. Some of these genetic changes could provide
a survival advantage for an emerging subclone that would
acquire a biallelic BRCA2 mutation. In MSI cells, however,
a highly elevated level of experimentation with mutations
is already present. Loss of BRCA2 function might not add
much to the rate of genetic experimentation in MSI cells
and could merely provide an inhibition of growth, mak-
ing it unlikely that these cells could outcompete other
subclones. Perhaps mutations in the BRCA2  gene are
likely to occur only in a narrow window of opportunity,
when an increase in genetic experimentation outweighs
the growth inhibition caused by the loss of BRCA2.
Methods
Samples
Pancreatic cancer cell lines PL3 and PL5 were gifts of Dr.
Elizabeth M. Jaffee (Johns Hopkins University). The pan-
creatic xenograft PX196 was established in our laboratory,
as previously described [29]. Colorectal cancer cell lines
LS174T and RKO, and genomic DNA for colorectal cell
lines LoVo, Vaco5, Vaco6, HCT116, C, VACC1430,
LIM1215, LIM2412, Vaco481 and KM12, were gifts of
Drs. Bert Vogelstein and Christoph Lengauer (Johns Hop-
kins University). The colorectal cell line MIP101 was a gift
of Dr. J. Milburn Jessup (Georgetown University). FN-1
cells are primary buccal mucosafibroblasts derived from a
healthy 11 year old boy; VH10 cells are primary fibrob-
lasts derived from the foreskin of a 10 year old healthy
boy. EUFA423/FA-D1 cells are primary fibroblasts from a
Fanconi anemia patient with complementation group D1
and are a kind gift of Dr. H. Joenje (Departement of Clin-
ical and Human Genetics, Free University Medical center,
Amsterdam, The Netherlands).
Sequencing
BRCA2  sequencing was performed by Myriad Genetics
Inc. (Salt Lake City, Utah). Primers for RT-PCR and con-
firmatory genomic sequencing were obtained from IDT-
DNA (Coralville, Iowa). The poly [T] tract in the MRE11
gene was analyzed by automated sequencing of PCR-
amplified genomic DNA. Prevalence rates of the muta-
tions were analyzed by the techniques described previ-
ously [5,10].
Immunofluorescence labeling and microscopy
To examine RAD51 foci formation, cells were grown on
sterile glass slides for two days, giving sub-confluent cells
at time of fixation. Then, cells were either mock-treated or
treated with MMC (2.4 µg/ml for 1 h) or irradiated with
12 Gy of X-ray. After an 8 or 24 h recovery period, cells
were fixed with 2% formaldehyde in PBS and permeabi-
lized for antibody staining with PBS/0.1% Triton X-100.
Subsequently the slides were blocked for 15 min in PBS/
BSA (0.5%)/glycin (0.15%) and thereafter incubated with
rabbit anti-HsRAD51 antiserum (FBE2) for 90 min at
37°C in a humidified atmosphere. The slides were
washed three times in PBS/0.1% Triton X-100 and then
incubated with AlexaTM 488-conjugated goat anti-rabbit
IgG (Molecular Probes) for 1 h at 37°C in a humidified
atmosphere. After three washes with PBS/0.1% Triton X-
100 the cells were counterstained with 4',6-diamino-2-
phenylindole (DAPI; 0.15 µg/ml) in Vectashield mount-
ing medium (Vector Laboratories). RAD51 foci were
examined under a Leitz Axioplan fluorescence micro-
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